We're going to run some new plays, and we think they're going to provide us some more momentum.
What we get is diversification for Boston Scientific and growth, and we get that through CRM. Clearly, CRM is the key asset here.
We use cookies to enhance your browsing experience, analyze site traffic, and personalize content. By clicking "Got It!," you consent to our use of cookies.
